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a b s t r a c t
JC virus (JCV) is a member of the Polyomaviridae family and is associated to a severe disease
known as progressive multifocal leukoencephalopathy, PML, which is gradually increas-
ing in incidence as an opportunistic infection among AIDS patients. The present study
aimed to investigate the occurrence of JCV among HIV-1 carriers including their types and
molecular subtypes and the possible association with disease. Urine samples from 66 HIV-1
infected subjects were investigated for the presence of the virus by amplifying VP1 (215bp)
and IG (610bp) regions using the polymerase chain reaction. JCV was detected in 32% of
the samples. The results conﬁrmed the occurrence of type B (subtype Af2); in addition,
another polyomavirus, BKV, was also detected in 1.5% of samples of the HIV-1 infected
subjects. Apparently, there was no signiﬁcant difference between mono- (HIV-1 only) and
co-infected (HIV-1/JCV) subjects regarding their TCD4+/TCD8+ lymphocyte counts or HIV-1plasma viral load. Self admitted seizures, hearing and visual loses were not signiﬁcantly
different between the two groups.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Although JCV is found to infect more than 70% of theIntroduction
Polyomaviruses are small agents which infect a variety of
species including man, non-human primates, cattle, rodents,
rabbits, and birds. Two human polyomaviruses are important
pathogens, JC virus (JCV) and BK virus (BKV), as they are able to
cause a severe, usually fatal, neurological disease (progressive
multifocal leukoencephalopathy, PML) and renal infection in
immunosupressed patients, respectively.1–3 The viruses share
∗ Corresponding author.
E-mail address: ivallinoto@ufpa.br (I.M. Cayres-Vallinoto).
http://dx.doi.org/10.1016/j.bjid.2016.05.005
1413-8670/© 2016 Elsevier Editora Ltda. This is an open access articl
licenses/by-nc-nd/4.0/).approximately 72% of nucleotide homology and a high degree
of identity (80%) of amino acid sequence of a capsid protein,
VP1.4,5 JCV infects the human host and establishes a persis-
tent replicative cycle (including latency) following the acute
infection, which favors its dissemination within human pop-
ulations and its carriage through generations.adult human population as a productively persistent infec-
tion, PML is a rare disease.5–9 It is a manifestation that
follows malignant conditions, as well as a consequence of
e under the CC BY-NC-ND license (http://creativecommons.org/
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rimary or secondary immunodeﬁciencies, particularly in
cquired immunodeﬁciency syndrome (AIDS). The emergence
f human immunodeﬁciency virus 1 (HIV-1) infection elicited
n additional interest in JCV with the frequent ﬁnding of
IV-1 carriers co-infected with JCV.10 The incidence of PML
s gradually increasing among AIDS patients, initially as a
onsequence of the increase of HIV-1 infections, and sec-
ndly, as an increase in life expectancy as a result of better
ntiretroviral drugs.10 JCV infects HIV-1 carriers and is one
f the major opportunistic infections of the central nervous
ystem.11–15 In our previous study we described JCV and BKV
nfections among Amerindian tribes, Afro-descendant com-
unities, as well as in the urban area of Belém, state of Para,
orth of Brazil.16 The results showed a large genetic variability
f strains circulating in the region, infecting a large group of
ndividuals. The presence of European, Asiatic, and African
ubtypes associated to the ethnic origin of the population
amples investigated highlighted the idea that JCV is a good
arker for studying the early migration of human popula-
ions, reﬂecting their early and late history.
The present study aimed to describe the occurrence of JCV,
ncluding their types and molecular subtypes among HIV-1
arriers and the possible association with neurological dis-
ase.
aterials and methods
opulation examined
cross-sectional study was performed, using a convenience
ample which included 66 HIV-1 infected persons. A single
rine sample was obtained from HIV-1 infected persons resid-
ng in the city of Belém, attending the University Hospital
oão de Barros Barreto (HUJBB), for their routine clinical care,
nd laboratory follow-up determinations of TCD4+/TCD8+
ymphocyte counts and HIV-1 plasma viral load (HPVL). All
atients were receiving antiretroviral therapy (ART) at the
ime of sample collection. The duration of ART ranged from
ne to seven years. Half of them were on ART for no more
han ﬁve years, with mean and median values of four years.
he project was approved by the Ethics Committee of the
niversity Hospital Joao de Barros Barreto (Protocol Num-
er 2092/05). The participants were briefed about the project
nd those who accepted to take part signed an informed
onsent. All patients were adults (18 years or older) and
ere capable to provide answers to a questionnaire which
ncludedquestions regardingdemographic, social and cultural
spects of their life style. The patients were also asked to
nform, over common neurological events which are usually
onsidered as baseline symptoms associated to JCV infec-
ion, at least once, since their initial diagnosis of HIV-1
nfection.
uantiﬁcation of HPVL and TCD4+/TCD8+ lymphocyte
ountsPVL was determined by the bDNA method (VERSANT® HIV-1
NA 3.0 Assay bDNA “Versant Assay”, Siemens, USA) follow-
ng the manufacturer’s directions. Whole blood samples were6;20(4):360–364 361
processed within four hours of collection for the determina-
tion of TCD4+ counts by ﬂow cytometry (FacsCount, Becton &
Dickinson, San Jose, CA, USA) using the FacsCountTM Reagents
immunomonitoring kit, following the protocol recommended
by the manufacturer (Becton Dickinson, San Jose, CA, USA).
Both procedureswere routinely conducted at the Virology Lab-
oratory, which is one of the National Reference Laboratory for
the two determinations.
Urine sample collection and DNA extraction
Urine samples (50mL) were collected in speciﬁc vial col-
lectors and transported to the Virology Laboratory of the
Institute of Biological Sciences of the Universidade Federal do
Para (ICB/UFPA) and stored at −20 ◦C until assaying for JCV
infection. The urine samples were centrifuged at 5000 rpm
for 15min, the urinary sediment washed three times with
sterile saline solution and the cell pellet used for DNA
extraction according to the protocol using the EZ-DNA kit
(Gentra Systems, Inc., Minneapolis, MN, USA), as previously
described.16
Molecular analysis
Polymerase chain reaction – PCR was performed for ampli-
ﬁcation of the VP1 gene (215bp) and the genomic region IG
(610bp) of JCV, using a thermocycler (Mastercycler Personal,
Eppendorf, Germany), and the ampliﬁed products were sub-
jected to puriﬁcation for subsequent sequencing analysis of
the nucleotide bases, as previously described.16
Sequencing and subtype analysis
The ampliﬁed products of the IG region were used for deter-
mining genetic relationships among the strains detected and
those recorded in Genbank database. The ampliﬁed frag-
ments were submitted to a direct sequencing assay (both
forward and reverse) according to the protocol of theABI Prism
Dye Terminator Cycle Sequencing Ready Kit (Life Technolo-
gies, Foster City, CA, USA) and the products were loaded on
the ABI Prism 310 DNA Sequencer (Life Technologies, Foster
City, CA, USA). The nucleotide sequences were used together
with other JCV sequences available in the Genbank as pre-
viously described.16 Nucleotides sequences obtained in the
present study are available in the Genbank databases under
theaccessionnumbersKR062063, KR062064andKR062065and
were submitted to Basic Local Alignment Search Tool – Blast
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) aiming to identify the
virus subtype.
Statistical analysis
The frequency of HIV-1/JCV co-infection was estimated by
direct counting. To determine whether the variables TCD4+,
TCD8+ and HIV-1 viral load followed a normal distribution,
D’Agostino’s test was used, and the mean values of the labo-
ratory markers were compared using ANOVA. A p-value <0.05
was considered statistically signiﬁcant using the BioEstat 5.0
software.17
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Table 1 – Distribution of HIV-1 carriers investigated for
JCV infection according to sex and age.
Age range Male (%) Female (%) Total (%)
11–20 0 1 1
21–30 10 6 16
31–40 18 9 27
41–50 10 4 14
>50 3 1 4
Table 2 – Frequency of self-admitted neurological
alterations among HIV-1 carriers and co-infected with
JCV.
Clinical symptoms HIV-1
carriers
(%)
JCV/HIV-1
coinfected (%)
Total
With neurological
symptoms
19 (46.3) 10 (52.6) 29 (48.3)
Without neurological
symptoms
22 (53.7) 9 (47.4) 31 (51.7)
Total 41 (100) 19 (100) 60 (100)
2No information 3 1 4
Total 44 (66.7) 22 (33.3) 66 (100)
Results
JCV infection was investigated in 66 urine samples of HIV-1
carriers, outpatients and inpatients, attending the University
Hospital. Table 1 shows that most of the patients were male
(66.7%), within the age range of 21–50 years old (86.4%).
Ampliﬁcation of VP1 was obtained in 21 (32%) samples
(18 males and 3 females) and 11 of them ampliﬁed the two
regions, VP1 and IG. Sequencing of nine samples from IG
region submitted to Basic Local Alignment Search Tool –
Blast (http://blast.ncbi.nlm.nih.gov/Blast.cgi) were identiﬁed
as belonging to type B, subtype Af2, with 100% identity, con-
ﬁrming the JCV/HIV-1 co-infection. The molecular analysis
also showed the ampliﬁcation of a nucleotide sequence of
541bp, characteristic of BKV polyomavirus, showing 97.4%
identitywith KOM-3 line and a co-infection BKV/HIV-1 in 1.5%.
TCD4+ and TCD8+ lymphocyte counts and HPVL (Fig. 1)
were compared between the mono-infected (HIV-1 only) and
co-infected (JCV/HIV-1) patients. The average counts of TCD4+
were 130.61 and 105.25 cells/mL (p=0.5649), and the values
for TCD8+ were 589.97 and 679.66 cells/mL (p=0.2416), respec-
tively. The mean values for HPVL (log10) were 4.563 and 4.867
(p=0.5605), respectively (Fig. 1).
Neurological events were investigated regarding the pres-
ence of seizures, as well as, hearing and vision losses (Table 2).
The presence of these baseline symptoms at least once after
laboratory diagnosis of HIV-1 infectionwere admitted by 46.3%
and 52.6%, of the mono and double infected individuals,
Fig. 1 – Comparison of the mean values of (A) TCD4+, (B) TCD8+ ly
HIV-1 and HIV-1/JCV infected patients. =0.031; p=0.860.
respectively, but the difference between the frequencies was
not signiﬁcant (p=0.860).
Discussion
The information obtained from HIV-1 carriers were sufﬁcient
to establish the socio demographic variables and indicate
possible trends of the infection. The age range observed
(20–60 years) was in agreement with the epidemic in Brazil.18
Similar results were seen in the USA with patients with non-
Hodgkin’s lymphoma, HIV-1 negative patients,19 and healthy
Koreans.20–23 It is believed that JCV infection occurs early in
life and therefore it is necessary to monitor the upsurge of
disease amonghealthy individuals orwith associatedpatholo-
gieswithindifferent population groups as the virus prevalence
is usually high.5,6,8,9
Infection was deﬁned by the presence of two codifying
genomic regions, VP1 and IG, which have been fairly corre-
lated with seroepidemiological information among different
populations.23–27 The variation of prevalence rates are also
commonly observed among HIV-1 carriers. The present work
showed 32% prevalence of co-JCV/HIV-1 infection, which is
similar to that reported by others amongHIV-1 carrierswith or
without LPM.7,8,28–32 The search for the virus in other biological
mphocyte counts and (C) mean of HIV-1 viral load between
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uids including urine, plasma, liquor and cerebral tissue did
ot increase signiﬁcantly the prevalence of JCV.30
Higher prevalence rates have been reported in Brazil in
he CSF of HIV-1 carriers,33 in Germany, in the blood,34 in
rance, in brain tissue and blood35,36 and in Italy, where very
igh and very low rates were described in the CSF of HIV-1
arriers.37,38
Co-infection with BKV is also a commonly reported ﬁnd-
ng among HIV-1 infected persons.8,39,40 There was only one
KV/HIV-1 co-infected person in the examined group, in con-
rast to what has been reported by other. The presence of
KV has been previously reported in our geographical area in
fro-descendants living in the region of Rio Trombetas, Para,6
mong renal patients and the general population of urban
enters.41 The low prevalence of BKV indicates its low levels
f dissemination.
HIV-1 infection was more frequent among males, which is
onsistent with the overall epidemic in Brazil.18 The observa-
ion of sex and age distribution of HIV-1 carriers or not, were
escribed by seven laboratories from England and Wales,7
mong aborigenes from Central Africa (pigmies and Ban-
us), in patients from general hospital in Australia, including
mmunocompromised persons,27 and in Brazil40 but there
ere no statistically signiﬁcant differences of prevalence
etween sexes.
TCD4+ andTCD8+ lymphocyte counts, aswell as,HIV-1 viral
oad were not different between mono- and double-infected
ubjects, which is a common ﬁnding,8,39,40,42 suggesting that
he frequencyof JCVsheddingmaynot be inﬂuencedor altered
y the immunodeﬁciency process, but it remains a matter of
ontroversy yet to be deﬁned.
The investigation of possible disease among the exam-
ned group was approached by a self-admitted present or past
ommon symptoms of major perception, including seizures,
earing and vision losses. There was no difference between
he frequencies found among the mono- and double-infected
roups. Although JCV is a major opportunistic infection of the
NS,11–15,43 PML is not commonly reported in Brazil.40 Either
e are not performing the correct diagnosis of minor and
ajor symptoms of PML, or reactivation of the virus, although
common feature, is without clinical consequences in HIV-
infected persons in the North and Southeast regions of the
ountry.
Until now, there have been few reports of JCV and BKV
f either mono-infection or HIV-1 co-infection in Brazil. The
esults obtained, so far, show a large frequency of excretion of
CV and sometimes of BKV. The clinical consequences of the
nfections with both viruses should not be ignored and should
eserve a deeper look into the actual clinical and epidemio-
ogical picture, including the improvement and dissemination
f laboratory diagnosis of both infections.
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